AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05636540
Drug: [18F]FluorThanatrace ([18F]FTT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A pre-treatment 18F-FluorThanatrace (\[18F\]FTT) positron emission tomography/computed tomography (PET/CT) scan will be done prior to surgery or systemic therapy.
Trial: NCT05331664
Drug: Prednisolone 1%
RxNorm normalized name: GENTAMICIN 0.3/PREDNISOLONE 1% OPH SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid eye drop 4 times per day tapered by one drop weekly for 4 weeks (4/3/2/1 taper) after surgery
Trial: NCT05062317
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by PO
Trial: NCT05062317
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT06378658
Drug: BAY2927088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05094154
Drug: anti-pseudomonal cephalosporin
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Providers will be prompted to order an anti-pseudomonal cephalosporin, such as cefepime with a dose range of 500 mg, 1,000 mg, or 2,000 mg, and frequency every 6, 8, 12, or 24 hours based on provider discretion.
Trial: NCT06624696
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The normal saline with a total volume of 5 mL will be added to the nebulizer cup for inhalation. Patients will be asked to inhale the entire volume of nebulized drugs within 30 min prior to surgery. The trial drugs will be administered using a jet nebulizer with compressed air flow. Each child will be intructed to begin the nebulization by using a face mask that covers the nose and mouth while the child is seated upright. Children will be encouraged to take deep and slow breaths, inhaling through the mouth and exhaling through the nose, to ensure the drugs effectively reaches the airway.
Trial: NCT06624878
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a placebo (an equivalent volume of normal saline) infused intravenously after induction of general anesthesia.
Trial: NCT05613426
Drug: Rosuvastatin 20 mg
RxNorm normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very early use of Rosuvastatin before primary PCI in anterior STEMI
Trial: NCT05751226
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05718687
Drug: GBT021601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
Trial: NCT05347771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The composition of the placebo for dupilumab is the same as the active study drug without the dupilumab.
Trial: NCT06361238
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Placebo: the same volume as liraglutide administrated at the corresponding times.
Trial: NCT05029726
Drug: Bupivacaine-Epinephrine 0.25%-1:200,000 Injectable Solution plus clonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-Epinephrine 0.25%-1:200,000 plus clonidine 50 micrograms in 30cc syringes administered as ESPB
Trial: NCT05029726
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline in 30cc syringes administered using ESPB technique
Trial: NCT05191862
Drug: PMR 135 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two PMR 135 mg at 08:00, single oral dose (total daily dose of 270 mg)
Trial: NCT05575804
Drug: pyrotinib+capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pyrotinib 400mg orally once daily in combination with capecitabine 1000mg/m2 twice daily, day1-14, every three weeks until disease progression or unacceptable toxicity.
Trial: NCT06693674
Drug: Entresto Pill
RxNorm normalized name: Entresto Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).
Trial: NCT05173272
Drug: Neoadjuvant Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m\^2 d1 q21+ Paclitaxel 175 mg/m\^2 d1 q21+serplulimab 300mg d1 q21
Trial: NCT05260008
Drug: bupivacaine hydrochloride without epinephrine
RxNorm normalized name: bupivacaine hydrochloride / epinephrine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine hydrochloride (125 mg) without epinephrine via local infiltration and/or nerve block
Trial: NCT05120349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
Trial: NCT06511011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granules for 6 weeks
Trial: NCT06307080
Drug: Intravenous anti-PD-1 and chemotherapy
RxNorm normalized name: Dianeal PD-2/1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous anti-PD-1 and chemotherapy
Trial: NCT04749108
Drug: Induction chemotherapy - modified FOLFIRINOX regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An induction chemotherapy (6 cycles) combining irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2 followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered every 15 days (D1=D15).
Trial: NCT06041529
Drug: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Trial: NCT06041529
Drug: Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily(QD), 8 weeks and 26 weeks if applicable
Trial: NCT05431582
Drug: ZN-c3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by PO 1 time a day with a glass (about 8 ounces) of water
Trial: NCT05874219
Drug: Local antibiotic spray Neomycin sulphate 165,000 IU + Bacitracin zinc 12,500 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention Sprayed 1 to 3 times /day
Trial: NCT06693518
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuzatrelvir 600 mg + Dabigatran Etexilate 150 mg
Trial: NCT06693518
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran Etexilate 150 mg
Trial: NCT04732416
Drug: HM15136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of HM15136/ High dose of HM15136, SC injection, weekly
Trial: NCT05269134
Drug: Bacteriophage
RxNorm normalized name: bacteriophages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phage Therapy
Trial: NCT05269134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05164952
Drug: Zoledronic Acid 4 MG
RxNorm normalized name: zoledronic acid 4 MG
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (4 mg via 15-min infusion every 6 months) for 24 months
Trial: NCT05272059
Drug: MHS552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
Trial: NCT05272059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)
Trial: NCT05496426
Drug: KL130008/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: KL130008 Drug: Placebo
Trial: NCT06256926
Drug: Test Product: Curcuvail® 250mg capsule (Curcuma longa Extractcontaining 35% Curcuminoids)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuma longa Extract containing 35% Curcuminoids Dose: One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
Trial: NCT06256926
Drug: Placebo product
RxNorm normalized name: placebo Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo product Dose:One capsule Frequency: Twice Daily Route of administration: Oral Duration of therapy: 60Days
Trial: NCT05923905
Drug: FB1006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/day
Trial: NCT05923905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg/day
Trial: NCT05795465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT00002089
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05668013
Drug: TEV-48574 Dose Regimen A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (sc) administration using a commercial sc infusion system
Trial: NCT04884035
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
Trial: NCT04884035
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
Trial: NCT05159700
Drug: PRJ1-3024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRJ1-3024 is provided as capsules and is administered orally once a day.
Trial: NCT06108830
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
Trial: NCT05727163
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 via HAI
Trial: NCT05727163
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 via HAI and 2.4g/m2 via HAI over 48 hours
Trial: NCT05727163
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2 intravenously
Trial: NCT05727163
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 intravenously + 2400 mg/m2 continuous intravenous infusion over 46 hours
Trial: NCT06427681
Drug: BH006 for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the random administration plan, the test product BH006 \[(fosaprepitant and palonosetron) for injection\] 150mg/0.25mg or the reference product \[EMEND® (fosaprepitant) for injection 150 mg + Palonosetron hydrochloride injection 0.25 mg) were injected, and crossovered after a sufficient washing period (14 days), dosing is carried out for the second cycle study.
Trial: NCT05740332
Drug: Alcohol hand sanitizer foam
RxNorm normalized name: BENZETHONIUM CHLORIDE 2.5 g in 1 L TOPICAL LIQUID [Sierra Soft Non-Alcohol Hand Sanitizer Foam]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)
Trial: NCT06171880
Drug: JLP-1901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of JLP-1901
Trial: NCT06171880
Drug: JC-001(active comparator)
RxNorm normalized name: eptacog alfa activated 0.001 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of JC-001(tenofovir)
Trial: NCT05001217
Drug: Conventional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa, dopamine agonist, Monoamine oxidase-B inhibitors, Catechol-O-methyltransferase inhibitors, etc.
Trial: NCT05001217
Drug: Chinese herbal medicine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Huanglian Wendan Decoction~2. Jin Gui Shen Qi Pill~3. Liu Wei Di Huang Pill plus Tian Ma Gou Teng Decoction~4. Bu Yang Huan Wu Decoction
Trial: NCT06672393
Drug: HS-10374-matched placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days
Trial: NCT06671509
Drug: YZJ-1139
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose, 20 mg tablet
Trial: NCT05032053
Drug: Antithrombotic drugs
RxNorm normalized name: Heparin group antithrombotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The purpose of our study is to observe the effect of various antithrombotic drugs on the prognosis of ischemic stroke patients with cerebral microbleeds.
Trial: NCT06693362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Menstrual blood derived mesenchymal stem cells（Men-MSCs）Placebo is administered via intravenous infusion, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5).The placebo must be thawed, and 3 vials of placebo must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
Trial: NCT06693362
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Menstrual blood derived mesenchymal stem cells（Men-MSCs) injection (SC01009) is administered via intravenous infusion, with a total dose of 9×10\^7 cells, divided into 3 separate infusions, conducted on alternate days (i.e., Day 1, Day 3, and Day 5), with each infusion consisting of 3×10\^7 cells.Before the infusion, SC01009 injection must be thawed, and 3 vials of SC01009 must be diluted into 500ml of compound electrolyte injection solution. The medication is administered via intravenous infusion, starting with a slow drip for the first 15 minutes (30-40 drops per minute), and completed within 120 minutes to ensure cell viability. During the infusion process, the infusion bag can be gently shaken appropriately to ensure even suspension of the cells.
Trial: NCT06694935
Drug: QX1206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QX1206 will be administered orally before bedtime
Trial: NCT06688292
Drug: Actein effervescent 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of respiratory affections characterized by thick and viscous hypersecretion due to acute bronchitis,chronic bronchitis and its exacerbation, pulmonary emphysema, mucoviscidosis and bronchiectasis.
Trial: NCT06686745
Drug: SIM0508 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every 28 days is one cycle. Multiple dose levels of SIM0508 will be explored in dose escalation, and determine the maximum tolerated dose.
Trial: NCT04873323
Drug: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period
Trial: NCT05814770
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP \> 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
Trial: NCT06095973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depending on the cohort, volume will be varied to administer. Volume to be matched with the active investigational drug in the respective cohort.
Trial: NCT04873323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of TS-142 placebo in the morning under fasting in each period
Trial: NCT06649747
Drug: AFA-281
RxNorm normalized name: ADAPTER,ASPIRA/FLUSH,LUER URESIL AFA-LL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A small molecule, orally available
Trial: NCT05441150
Drug: 0.9% NaCl infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same dose of 0.9% NaCl infusion as the dose of ketamine for Control Group.
Trial: NCT06324851
Drug: Ethinylestradiol / Dienogest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial polyps underwent hysteroscopic polipectomy after starting 14-day treatment with oral Ethinylestradiol/Dienogest at any time of the menstrual cycle
Trial: NCT05930925
Drug: [phenyl-14C]ARV-471
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of \[phenyl-14C\]ARV-471 by mouth
Trial: NCT05930925
Drug: [oxoisoindolin-14C]ARV-471
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of \[oxoisoindolin-14C\]ARV-471 by mouth
Trial: NCT05416931
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application to painful area
Trial: NCT05619289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-time, oral dose of 6 inert capsules matched to the active comparator
Trial: NCT05106972
Drug: UC-MSC infusion
RxNorm normalized name: Astri-UC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UC-MSC infusion by introvenus
Trial: NCT04742153
Drug: MRG002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT06099873
Drug: ZX-7101A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day1 Take one tablet of ZX-7101A orally once (specification: 40mg/ tablet) with appropriate amount of warm water
Trial: NCT06099873
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day1 Take one tablet of Placebo orally once with appropriate amount of warm water
Trial: NCT05022004
Drug: Azopt®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose: one drop of study medication; frequency: three times a day; route of administration: Topical ocular administration; duration of therapy: 6 weeks
Trial: NCT04631471
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing dose of matching placebo from 6 capsules per day to 10 capsules per day to be started up to 10 weeks prior to surgery. Treatment will continue up to 24 weeks after surgery. Maximum treatment period will be of 34 weeks.
Trial: NCT06321484
Drug: Interleukin 2
RxNorm normalized name: Recombinant interleukin 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose subcutaneous IL-2 will be administered every other day for 5 doses after CIML NK cell infusion
Trial: NCT05707845
Drug: Medical treatment.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment in the form of nonsteroidal anti-inflammatory drugs (NSAIDs).
Trial: NCT05238896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 4 mg/d, oral route for 7 days, then Baricitinib 4 mg/d oral route for 5 weeks
Trial: NCT04628793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be prepared as an oral solution and/or suspension given in each cohort
Trial: NCT04518293
Drug: Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single pill
Trial: NCT04518293
Drug: telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Signle pill
Trial: NCT06186414
Drug: SIM0237
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RD level of SIM0237 will be administered as a single agent for evaluation
Trial: NCT04518293
Drug: Telmisartan 20 mg/indapamide 1.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04518293
Drug: telmisartan 40 mg/indapamide 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04518293
Drug: Amlodipine 2.5 mg/indapamide 1.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04518293
Drug: amlodipine 5 mg/indapamide 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT06205316
Drug: Antiandrogen Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive ADT
Trial: NCT04760314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04760314
Drug: Topical Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-applied
Trial: NCT06636617
Drug: 3.70 GBq (100 mCi) of 177Lu-JH04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All 3 patients were intravenous injected with single dose 3.70 GBq (100 mCi) of 177Lu-JH04.
Trial: NCT06636617
Drug: 5.55 GBq (150 mCi) of 177Lu-JH04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All 3 patients were intravenous injected with single 5.55 GBq (150 mCi) of 177Lu-JH04
Trial: NCT06636617
Drug: 7.40 GBq (200 mCi) of 177Lu-JH04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All 3 patients were intravenous injected with single 7.40 GBq (200 mCi) of 177Lu-JH04
Trial: NCT05716607
Drug: OD dual-release Hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with once-daily dual-release hydrocortisone
Trial: NCT05716607
Drug: TID Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment with thrice-daily conventional immediate-release hydrocortisone
Trial: NCT06627088
Drug: LY4100511 (DC-853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered oral dose